BOSTON and LEXINGTON, Mass., Feb. 15, 2024 /PRNewswire/ --The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium (MCDC) requirement 22-05, "Adjuvant Activity to Vaccines Prototype," a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks, Inc. (NYSE: DNA) and SaponiQx, Inc. (a subsidiary of Agenus Inc.,NASDAQ:AGEN) to discover and develop next-generation vaccine adjuvants. Partners in adjuvant discovery and development since 2021, Ginkgo, which is building the leading platform for cell programming and biosecurity, and SaponiQx, developing a visionary adjuvant development platform, will use a combination of high-throughput empirical and artificial intelligence/machine learning approaches, including Generative Molecular Design (GMD), to develop superior novel saponin-based adjuvants.
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination. Currently, only a handful of adjuvants are available for human use in licensed vaccines. SaponiQx's STIMULON QS-21 is a key adjuvant component in market-leading vaccines for shingles, malaria, and respiratory syncytial virus. Novel adjuvants with enhanced properties, including tailored humoral and cellular immune responses, could pave the way for a new wave of innovative vaccines against existing and emerging pathogens.
"The COVID-19 pandemic revealed the critical need for safe, effective, and accessible vaccines against emerging biothreat agents," said Jennifer Wipf, SVP, Head of Commercial Cell Engineering at Ginkgo Bioworks. "Imagine a future where vaccines are not only more affordable but also provide consistent protection in fewer doses, without causing discomfort or requiring refrigeration. We're very excited by this opportunity to strengthen and expand the SaponiQxGinkgo partnership and to work with DTRA to make that future a reality."
"Building on our achievements with STIMULON QS-21, SaponiQx is excited to realize our company's founding vision of harnessing the potential of Generative Molecular Design to dramatically increase access to lifesaving vaccines around the world," said Rebecca Kurnat, Head of Operations at SaponiQx.
The partners aim to demonstrate in the laboratory and in animal studies the ability of these novel adjuvants to protect against challenges from biothreat agents, such as the plague, and to provide lower cost, sustainable and scalable manufacturing processes by leveraging Ginkgo's leading platform for cell programming. The partners intend to design candidate adjuvants using SaponiQx's leading platform for adjuvant generation, and to identify additional candidates by screening natural extracts for previously uncharacterized saponins and creating non-natural saponins with enzyme-based techniques. Harnessing a first-of-its-kind "data lake" for adjuvants, they plan to use iterative GMD to propose and optimize adjuvant structures against eight functional parameters. Adjuvant candidates will be put through in-depth testing, first in the laboratory for immune and toxicity responses, and then in studies of their effectiveness in protecting vaccinated animals from pathogens; QS-21 and the related QS-7 will serve as benchmarks.
By leveraging Ginkgo's leading platform for cell programming, the partners also intend to develop more affordable, sustainable, and scalable adjuvant manufacturing processes. Ginkgo will develop a first-generation Adjuvant Development Candidate (ADC) production method, using a heterologous production strain such as brewers' yeast, Saccharomyces cerevisiae. Ginkgo's platform powers iterative DesignBuildTestLearn-driven cell engineering to enable the rapid prototyping, optimization, and development of proteins, enzymes, metabolic pathways, and whole organisms under commercial-scale manufacturing conditions. Development of a first-generation ADC production method could facilitate further development of a sustainable mass-production manufacturing process for these complex adjuvants.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visitginkgobioworks.com andconcentricbyginkgo.com, read ourblog, or follow us on social media channels such as X (formerly known as Twitter) (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), Threads (@GinkgoBioworks) orLinkedIn.
About SaponiQx
Founded in 2021, SaponiQx, a subsidiary of Agenus Inc., stands at the forefront of saponin-based adjuvant discovery and manufacturing. Its mission is to provide scalable and affordable vaccine adjuvants to enhance global health. Its proprietary adjuvant, STIMULON QS-21, forms an integral part of the AS01 adjuvant used in several leading vaccines. STIMULON is a trademark of Agenus Inc., the parent company of SaponiQx Inc.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on November 8, 2023 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
GINKGO BIOWORKS INVESTOR CONTACT:
[emailprotected]
GINKGO BIOWORKS MEDIA CONTACT:
[emailprotected]
Forward-Looking Statements of SaponiQx
This press release includes forward-looking statements, subject to risks and uncertainties, concerning the development of vaccines and adjuvants. Refer to the Risk Factors in Agenus' latest Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the SEC for a detailed discussion of these risks.
SAPONIQX MEDIA CONTACT:
SOURCE Ginkgo Bioworks
Continued here:
- Booster dose of the Pfizer-BioNTech/BNT162b2 COVID19 vaccine | IDR - Dove Medical Press [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Monkeypox vaccines have arrived in Victoria. Here's how the rollout will work - ABC News [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- UHD, H-E-B Offering Students Bacterial Meningitis Vaccine On Campus With Deferred Payment Option - UHD News [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative... [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Japan plans booster shots of Omicron vaccine in October | The Asahi Shimbun: Breaking News, Japan News and Analysis - [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- EyeGene to conduct vaccine projects with government support - KBR [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Monkeypox Vaccine: Where to Get It - countynewscenter.com [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- Vaccines for Covid-19 arent required in schools this fall - Vox.com [Last Updated On: August 9th, 2022] [Originally Added On: August 9th, 2022]
- 600 in Wisconsin receive monkeypox vaccination, says health department - Green Bay Press Gazette [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Effectiveness of third vaccine dose for coronavirus disease 2019 during the Omicron variant pandemic: a prospective observational study in Japan |... [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Why Monkeypox Vaccine Shortage May Threaten the Immunocompromised - The New York Times [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- UK will run out of monkeypox vaccine in 10 to 20 days - The Guardian [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19 - UMN News [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Phillys monkeypox vaccine shortages arent solved yet as feds make move to increase access to the shots - The Philadelphia Inquirer [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Vaccines are now approved for children aged six months to five years, but what about newborn babies? - ABC News [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- Bottling the monkeypox vaccine could take until early 2023 - POLITICO [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- The Brazilian Scientists Inventing An mRNA Vaccine And Sharing The Recipe : Short Wave - NPR [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- 2,000 Monkeypox Vaccine Appointments Are Available in Chicago This Weekend. Here's How to Get One - NBC Chicago [Last Updated On: August 11th, 2022] [Originally Added On: August 11th, 2022]
- 'Vaccine fatigue' could hit autumn Covid boosters | News | The Sunday Times - The Times [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Q&A: The new COVID vaccine booster is coming. Should you get it? - The Lawton Constitution [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Former CRH surgeon who survived polio disheartened by vaccination lapses - The Republic [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- 'Only the beginning': Hundreds protest Western University vaccine mandate - CBC.ca [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Vaccine hesitancy and trust in health experts: Shifting the focus - Medical News Today [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- I Was There When: AI helped create a vaccine - MIT Technology Review [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- The USDA is sprinkling fish-flavored vaccines from the sky to fight rabies - CNN [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- COVID-19 Vaccines | FDA [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Novavax COVID-19 vaccine available for ages 12 and up; CDC Community Level back at Low - Communications and Outreach - New Hanover County [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- Vaccine Definition & Meaning - Merriam-Webster [Last Updated On: August 28th, 2022] [Originally Added On: August 28th, 2022]
- National health agency apologises over Covid vaccine ads it was ordered to remove - RNZ [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Editorial: How Jewish space lasers and vaccine nanobots seized the brains of GOP voters - St. Louis Post-Dispatch [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Novel HER2-hICD Vaccine to be Investigated for Treatment of HER2-Low Breast Cancer - Targeted Oncology [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Brazilian Covid vaccine to be tested in humans in 2023 - The Brazilian Report [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- A Review on the Use of the HPV Vaccine in the Prevention of Cervical Cancer - Cureus [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- City Offering Second Doses of Monkeypox Vaccine to New Yorkers and Begin Accepting Walk-In Appointments - nyc.gov [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Monkeypox vax has disproportionately gone to white Philadelphians. This clinic sought to balance that. - The Philadelphia Inquirer [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Hopeful New Entry In The Race For A Universal Covid Vaccine - Forbes [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Study raises concerns about the effectiveness of the monkeypox vaccine - STAT [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- newsroom.heart.org [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- Did the affordable, no-patent COVID vaccine Corbevax live up to its promise? : Goats and Soda - NPR [Last Updated On: September 3rd, 2022] [Originally Added On: September 3rd, 2022]
- In CDC Survey of Over 13,000 Children, More Than Half Had 'Systemic Reaction' After COVID-19 Vaccine - The Epoch Times [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Department of Health working with community to administer monkeypox vaccines - Honolulu Star-Advertiser [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Fact check: Post-vaccine hospitalization odds not 3 times higher as ex-Japan PM claimed - The Mainichi - The Mainichi [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Impact of vaccinia virus-based vaccines on the 2022 monkeypox virus outbreak - News-Medical.Net [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Microsoft and Unicef drive Covid-19 vaccine roll-out with COVAX platform - Technology Record [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- School Mask, Vaccine Mandates Are Mostly Gone. But What if the Virus Comes Back? - The 74 [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in... [Last Updated On: September 6th, 2022] [Originally Added On: September 6th, 2022]
- Getting a Grip on Influenza: The Pursuit of a Universal Vaccine (Part 4) - Forbes [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- Why So Few Young Kids Are Vaccinated against COVIDAnd How to Change That - Scientific American [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- UK Travel Vaccine Market Report 2022: Increasing Travel and Tourism & Growing Incidences of Infectious Diseases Fuel Sector -... [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- At long last, we might have an HIV vaccine - Big Think [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- The associations between vaccination status, type, and time since vaccination with lineage identity during the emergence of new SARS-CoV-2 variants -... [Last Updated On: September 7th, 2022] [Originally Added On: September 7th, 2022]
- Needle-less COVID-19 vaccine developed at Washington University approved for use in India - KSDK.com [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Study: COVID-19 Vaccine Prevented Approximately 27 Million Infections in US Adults - Pharmacy Times [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Health System Warns Exemptions to COVID Vaccines May Expire With New Options - Medpage Today [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Does Moderna's vaccine IP lawsuit herald the end of the pandemic? - Medical Marketing and Media [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- The Unintended Consequences of COVID-19 Vaccine Policy The Wire Science - The Wire Science [Last Updated On: September 10th, 2022] [Originally Added On: September 10th, 2022]
- Astrocytes, the Covid vaccine and the 2021 classification - Brain Tumour Research [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Nearly 50 Members of Congress Call on Pentagon to End Military Vaccine Mandate - The Epoch Times [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- New Omicron-fighting Covid vaccine supplied with flimsy needles across Scotland to get replacement syringes - STV News [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Is There A Minimum Age for the Shingles Vaccine? - Healthline [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Detection of circulating vaccine derived polio virus 2 (cVDPV2) in environmental samples the United Kingdom of Great Britain and Northern Ireland and... [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- 850 more unvaxxed NYC teachers, aides fired for not complying with mandate - New York Post [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- 'India's vaccine growth story' book review: Far from being a dry collection of facts and figures - The New Indian Express [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Health care workers appeal dismissal of lawsuit over Maine's vaccine mandate - Kennebec Journal and Morning Sentinel [Last Updated On: September 18th, 2022] [Originally Added On: September 18th, 2022]
- Department of Health Expands Eligibility for the Monkeypox Vaccine - Anne Arundel County Department of Health [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Could This Be Pfizer's Next Billion-Dollar Vaccine? - The Motley Fool [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Many Vaccinated Youth Who Suffered Heart Inflammation Had Abnormal MRI Results Months Later: CDC Study - The Epoch Times [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Second vaccine doses to be offered to those at highest risk from monkeypox - GOV.UK [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies - Nature.com [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Coronavirus Roundup: A CDC Team Is Honored for Its Vaccine Distribution Work - GovExec.com [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Everything to know about the Monkeypox vaccine | Health - Red and Black [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- The U.S. ordered 171 million updated COVID booster shots but only 4.4 million went into arms as Biden says the pandemic is over - Fortune [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Why mosquitoes were the vaccinators in a new malaria vaccine trial : Goats and Soda - NPR [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Lyme disease is on the rise. Why is there still no vaccine? - AAMC [Last Updated On: September 25th, 2022] [Originally Added On: September 25th, 2022]
- Government of Canada announces funding for advancements in mRNA vaccine technology at the University of British Columbia - Canada NewsWire [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- 130 people have received incorrect doses of COVID-19 vaccines: MOH - CNA [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- Health unit hosts pop-up vaccine clinics throughout the week - BradfordToday [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- Doctor who gave anti-vaccine speech in front of effigies of officials being hanged faces discipline hearing - CBC.ca [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- What's really happening with global vaccine access? - Gavi, the Vaccine Alliance [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]
- Study confirms link between COVID-19 vaccination and temporary increase in menstrual cycle length - National Institutes of Health (.gov) [Last Updated On: October 3rd, 2022] [Originally Added On: October 3rd, 2022]